Post-launch Product Manufacture

At the end of the drug development journey together we may reach commercial drug launch. Avecia has a full complement of assets to allow for the manufacture of hundreds of kilograms of oligonucleotides per year, and we are able to offer the option of a dedicated or multi-product plant. We can manage the transition from Phase III manufacture and process validation to established launched drug API manufacture.